Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: KeepItSimple who wrote (172)	12/15/2003 12:21:51 PM
From: scaram(o)uche	Respond to of 411

Have you considered the possibility that Ranexa failure, complete, is in the stock? The Advisory Committee handed the molecule back to them and told them to find a patient population that will benefit. And, while it sets the stage for WONDERFUL upside in about 10 years, Lange's "the new science of QTc" bravado was mere face-saving IMO. You popped in and pronounced that the share price was going down. It didn't, because many believe that CVT-510 and/or CVT-3146 can support a share price below cash and at a modest multiple to book. IMO, your risk:exposure sucks, short. Dunno, but you're looking pretty green to me..... looking for blood from a stone, deriving information from Yahoo of all places, and exposed to any good news from the pipe. May be wrong, good luck!!